« Return to News | CROs/Service Providers | Drug Sponsors

WuXi reports 2Q revenue growth after Charles River deal fails

Friday, August 6, 2010 08:45 AM

Shanghai-based WuXi PharmaTech will receive a breakup fee of $30 million from Charles River Laboratories International, whose previously announced purchase of Wuxi was terminated by mutual agreement due to Charles River shareholder opposition.

"WuXi's strategy has not changed. Our goal is, and has long been, to build a broad, integrated R&D service platform designed to help our customers improve the success of research and shorten the time of new product development," said Dr. Ge Li, chairman and CEO. "While we are disappointed that this transaction could not be completed, WuXi remains well positioned to meet our customers' needs and to continue to grow and expand as a standalone company."

Wuxi reported that second-quarter 2010 net revenues increased 21% year over year to $81 million. Laboratory Services net revenues increased 18% and Manufacturing Services net revenues jumped 55%. Revenue growth in Laboratory Services was strong in both discovery chemistry and downstream services and in both China and the United States.

Revenue growth in Manufacturing Services was driven by increasing demand for clinical trial supplies. Second-quarter 2010 GAAP net income declined 6% year over year to $13.8 million.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.